Direct-to-Consumer Advertising and Shared Liability for Pharmaceutical Manufacturers
- 22 January 2003
- journal article
- editorial
- Published by American Medical Association (AMA)
- Vol. 289 (4) , 477-481
- https://doi.org/10.1001/jama.289.4.477
Abstract
During the last several years, the marketing of prescription drugs has undergone substantial change, facilitated by changes in the regulatory environment governing direct-to-consumer advertising (DTCA). Since the release in 1997 of new draft guidance by the Food and Drug Administration (FDA),1 consumer-oriented drug marketing has become pervasive, particularly in broadcast media. Ninety-one percent of US individuals report having seen consumer-oriented drug advertisements, and the pharmaceutical industry spent nearly $2.5 billion on DTCA in 2000.2Keywords
This publication has 19 references indexed in Scilit:
- Drugs-Herbals WorkshopPublished by American Medical Association (AMA) ,2002
- Direct-to-Consumer Advertising — Strengthening Our Health Care SystemNew England Journal of Medicine, 2002
- Are Patients' Office Visits with Physicians Getting Shorter?New England Journal of Medicine, 2001
- Informed Decision Making in Outpatient PracticeJAMA, 1999
- Doctors feel pressurised by direct to consumer advertisingBMJ, 1999
- Direct-to-consumer prescription drug advertising and the publicJournal of General Internal Medicine, 1999
- Counseling Patients About Prescribed MedicationMedical Care, 1997
- Products Liability and Prescription Drug Prices in Canada and the United StatesThe Journal of Law and Economics, 1997
- Direct-to the-Public Advertisement of Prescription DrugsNew England Journal of Medicine, 1988
- Safety and the Second Best: The Hazards of Public Risk Management in the CourtsColumbia Law Review, 1985